endothelin-1 and Angina--Stable

BACKGROUND The aim of this study was to investigate the effects of puerarin on vascular endothelial function and inflammatory factors in coronary artery disease (CAD) patients with stable angina pectoris (SAP). MATERIAL AND METHODS To evaluate the effects of angina pectoris, the differences of scores of the Seattle angina questionnaire (SAQ), vascular endothelial function [endothelial progenitor cells (EPCs), nitric oxide (NO) and endothelin 1 (ET-1)], and inflammatory factors [tumor necrosis factor a (TNF-α), hypersensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6)] in 2 groups were assessed before and after treatment. RESULTS Regarding the curative effect of angina pectoris, the total effective rate of the treatment group was significantly superior to that of the control group (89% vs. 65%, P<0.05). The duration of angina pectoris, the number of abnormal leads, the improvement of the ST segment depression of electrocardiogram, and the scores of SAQ life quality indexes in the treatment group were better than those of the control group (P<0.05). In the 2 groups, EPCs and NO were both elevated, while ET-1 was decreased, and the improvements of the treatment group were superior to those of the control group (P<0.05). After treatment, the average levels of serum TNF-α, hs-CRP and IL-6 in the 2 groups were all decreased, which the treatment group showed a much sharper decrease than in the control group (P<0.05). CONCLUSIONS Puerarin effectively improves clinical symptoms and vascular endothelial function and reduces the levels of inflammatory factors in patients with CAD.

Topics: Aged; Angina Pectoris; Angina, Stable; C-Reactive Protein; China; Coronary Artery Disease; Endothelial Cells; Endothelial Progenitor Cells; Endothelin-1; Female; Humans; Inflammation; Interleukin-6; Isoflavones; Male; Middle Aged; Nitric Oxide; Treatment Outcome; Tumor Necrosis Factor-alpha

The purpose of the study was to evaluate the influence of beta-blockers and ivabradine on long-term prognosis of patients with stable angina. 90 patients with stable angina that have been involved in present study along with nitrates, antiplatelet agents and statins received bisoprolol (Group I), carvedilol (Group II) and ivabradine (Group III). We analyzed the following indicators: patient adherence to treatment, cases of myocardial infarction and circulatory decompensation, which resulted in necessity of patient's hospitalization during the year of observation, calculating the probability of achieving a key prognostic endpoint by patient using the concept of the odds ratio and determination of important components in the progression of the disease. We concluded that in compared patients groups developed cardiovascular death and unstable angina with almost equal frequency. As for cases of myocardial infarction and the need for revascularization, their number was smaller in patients who in addition to standard treatment received ivabradine. Prognosis of patients with stable angina after 12 months of treatment primarily depends on their adherence to treatment, age, heart rate, presence of harmful habits, and markers of endothelial dysfunction, including endothelin-1 and homocysteine.

Topics: Adrenergic beta-Antagonists; Angina, Stable; Benzazepines; Biomarkers; Drug Therapy, Combination; Endothelin-1; Endothelium, Vascular; Homocysteine; Humans; Ivabradine; Medication Adherence; Middle Aged; Prognosis; Time Factors